Pneumagen has raised £3.8m to advance manufacturing of its lead product Neumifil.
The St Andrews-based clinical stage biotech company has now secured £14m worth of capital to date, with the latest investment letting it advance clinical development to the next stage.
Neumifil is being developed to offer pan-antiviral protection against respiratory viruses such as influenza, respiratory syncytial virus and coronaviruses - including SARS-CoV-2 - with a self-administered nasal spray
